Alexion closed the final agreement to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn), for an upfront payment of $400 million and additional milestone-dependent payments of up to $800 million.

Syntimmune’s lead candidate, SYNT001, is a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes currently in Phase 1b/2a studies in patients with warm autoimmune hemolytic anemia and in patients with pemphigus vulgaris or pemphigus foliaceus. It has demonstrated proof of mechanism showing rapid IgG reduction.


Please enter your comment!
Please enter your name here